These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 38306361)
21. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene. Mala U; Baral TK; Somasundaram K BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717 [TBL] [Abstract][Full Text] [Related]
22. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832 [TBL] [Abstract][Full Text] [Related]
23. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588 [TBL] [Abstract][Full Text] [Related]
24. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073 [TBL] [Abstract][Full Text] [Related]
25. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956 [TBL] [Abstract][Full Text] [Related]
26. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724 [TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes. Patil V; Mahalingam K Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645 [TBL] [Abstract][Full Text] [Related]
28. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells. Zorniak M; Clark PA; Kuo JS J Neurosurg; 2015 Jan; 122(1):69-77. PubMed ID: 25361488 [TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and genomic features of gliosarcomas. Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848 [TBL] [Abstract][Full Text] [Related]
30. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191 [TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. von Achenbach C; Weller M; Szabo E J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622 [TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096 [TBL] [Abstract][Full Text] [Related]
33. Regulation and function of aquaporin-1 in glioma cells. Hayashi Y; Edwards NA; Proescholdt MA; Oldfield EH; Merrill MJ Neoplasia; 2007 Sep; 9(9):777-87. PubMed ID: 17898873 [TBL] [Abstract][Full Text] [Related]
34. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Campos B; Wan F; Farhadi M; Ernst A; Zeppernick F; Tagscherer KE; Ahmadi R; Lohr J; Dictus C; Gdynia G; Combs SE; Goidts V; Helmke BM; Eckstein V; Roth W; Beckhove P; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende C Clin Cancer Res; 2010 May; 16(10):2715-28. PubMed ID: 20442299 [TBL] [Abstract][Full Text] [Related]
35. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078 [TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385 [TBL] [Abstract][Full Text] [Related]
38. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
39. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]